Dupilumab in the management of moderate-to-severe asthma: the data so far.

about

Biologic Targeting: New and Effective Therapeutic Approaches against Severe Asthma.Anticalin® Proteins as Therapeutic Agents in Human Diseases.Precision Medicine in Targeted Therapies for Severe Asthma: Is There Any Place for “Omics” Technology?

P2860

Q52564875-76C8D26B-252C-42CB-B561-B469FF4E1EDA Q55484632-3DF5AE28-7D80-4FB2-BE19-C0358FBCE197 Q55501424-137EC3DC-4D93-4E26-B56D-D3BABD73B16F

P2860

Dupilumab in the management of moderate-to-severe asthma: the data so far.

Item

http://www.wikidata.org/entity/Q42229455

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Dupilumab in the management of moderate-to-severe asthma: the data so far.

@en

Dupilumab in the management of moderate-to-severe asthma: the data so far.

@nl

type

Item

label

Dupilumab in the management of moderate-to-severe asthma: the data so far.

@en

Dupilumab in the management of moderate-to-severe asthma: the data so far.

@nl

prefLabel

Dupilumab in the management of moderate-to-severe asthma: the data so far.

@en

Dupilumab in the management of moderate-to-severe asthma: the data so far.

@nl

P1476

Dupilumab in the management of moderate-to-severe asthma: the data so far.

@en

P2093

Javier Dominguez-Ortega

http://www.w3.org/2001/XMLSchema#string

Pilar Barranco

http://www.w3.org/2001/XMLSchema#string

Santiago Quirce

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system

Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma

Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists.

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

Biologics in asthma--the next step toward personalized treatment

Antibodies to watch in 2015

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Lebrikizumab treatment in adults with asthma.

Targeting interleukin-4 in asthma: lost in translation?

Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma.

P304

1139-1149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S125964

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elsa Phillips-Angles

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28979129

http://www.w3.org/2001/XMLSchema#string

P921

asthma

P932

5589101

http://www.w3.org/2001/XMLSchema#string

Dupilumab in the management of moderate-to-severe asthma: the data so far.

about

P2860

P2860

Dupilumab in the management of moderate-to-severe asthma: the data so far.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932